Bank of America’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-95,600
| Closed | -$10.8M | – | 8153 |
|
|
2023
Q3 | $10.8M | Buy |
+95,600
| New | +$10.1M | ﹤0.01% | 2647 |
|
|
2021
Q4 | – | Sell |
-9,200
| Closed | -$882K | – | 8486 |
|
|
2021
Q3 | $882K | Buy |
+9,200
| New | +$869K | ﹤0.01% | 5193 |
|
|
2021
Q2 | – | Sell |
-100
| Closed | -$10K | – | 7963 |
|
|
2021
Q1 | $10K | Buy |
+100
| New | +$10.5K | ﹤0.01% | 7012 |
|
|
2020
Q4 | – | Sell |
-5,000
| Closed | -$481K | – | 7272 |
|
|
2020
Q3 | $481K | Sell |
5,000
-24,400
| -83% | -$2.82M | ﹤0.01% | 4746 |
|
|
2020
Q2 | $3.59M | Buy |
29,400
+8,800
| +43% | +$972K | ﹤0.01% | 3152 |
|
|
2020
Q1 | $1.78M | Buy |
20,600
+17,500
| +565% | +$1.71M | ﹤0.01% | 3569 |
|
|
2019
Q4 | $333K | Buy |
+3,100
| New | +$325K | ﹤0.01% | 5301 |
|
|
2019
Q3 | – | Sell |
-103,200
| Closed | -$8.71M | – | 7407 |
|
|
2019
Q2 | $8.71M | Buy |
103,200
+52,100
| +102% | +$4.28M | ﹤0.01% | 2698 |
|
|
2019
Q1 | $4.5M | Buy |
+51,100
| New | +$4.27M | ﹤0.01% | 3260 |
|
|
2018
Q3 | – | Sell |
-24,800
| Closed | -$2.44M | – | 7399 |
|
|
2018
Q2 | $2.44M | Buy |
+24,800
| New | +$2.22M | ﹤0.01% | 3818 |
|
|
2017
Q4 | – | Sell |
-6,300
| Closed | -$386K | – | 7168 |
|
|
2017
Q3 | $386K | Buy |
+6,300
| New | +$332K | ﹤0.01% | 5094 |
|
|
2017
Q2 | – | Sell |
-14,900
| Closed | -$645K | – | 7090 |
|
|
2017
Q1 | $645K | Buy |
+14,900
| New | +$638K | ﹤0.01% | 4715 |
|
|
2016
Q2 | – | Sell |
-76,700
| Closed | -$3.03M | – | 7277 |
|
|
2016
Q1 | $3.03M | Buy |
+76,700
| New | +$3.04M | ﹤0.01% | 3211 |
|
|
2015
Q2 | – | Sell |
-60,000
| Closed | -$2.38M | – | 7363 |
|
|
2015
Q1 | $2.38M | Buy |
60,000
+55,300
| +1,177% | +$1.98M | ﹤0.01% | 3076 |
|
|
2014
Q4 | $105K | Buy |
4,700
+900
| +24% | +$17.1K | ﹤0.01% | 5848 |
|
|
2014
Q3 | $60K | Sell |
3,800
-46,500
| -92% | -$695K | ﹤0.01% | 6386 |
|
|
2014
Q2 | $746K | Buy |
50,300
+42,800
| +571% | +$604K | ﹤0.01% | 4242 |
|
|
2014
Q1 | $121K | Buy |
+7,500
| New | +$128K | ﹤0.01% | 5831 |
|
|
2013
Q4 | – | Sell |
-25,000
| Closed | -$283K | – | 8043 |
|
|
2013
Q3 | $283K | Sell |
25,000
-13,800
| -36% | -$190K | ﹤0.01% | 5138 |
|
|
2013
Q2 | $519K | Buy |
+38,800
| New | +$477K | ﹤0.01% | 4709 |
|
Other funds holding NBIX
VPM
VCM
Bank of America's NBIX Position: Q1 2026 in Review
Bank of America increased its Neurocrine Biosciences (NBIX) stake by 11% in Q1 2026, buying an estimated $7.39M and bringing the position to 583,827 shares worth $76.9M. The position accounts for 0.01% of the portfolio, ranked #1308.
Bank of America first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $98.9M in Q3 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Bank of America held 583,827 shares of Neurocrine Biosciences worth $76.9M as of Q1 2026.
- Bank of America bought 55,723 Neurocrine Biosciences shares in Q1 2026, an estimated $7.39M.
- Neurocrine Biosciences made up 0.01% of Bank of America's portfolio in Q1 2026, its #1308 holding.
- Bank of America first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Neurocrine Biosciences position peaked at $98.9M in Q3 2025.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.